Effect of genetic polymorphism on the activity of drug transporters and its clinical significance

Journal of Central South University (Medical Sciences)

Volumn 33, Issue 8, 2008, Pages 765-769

  Zhang, Hai Xia ^a   Wang, Lian Sheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genetic poly; Morphism; Multidrug resistance protein; Organic anion transport proteins

Indexed keywords

CARRIER PROTEIN; DRUG; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER;

DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; REVIEW;

DRUG INTERACTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 53649095479     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J]. Proc Natl Acad Sci USA, 2000,97(7):3473-3478.
2. Ameyaw M M, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity[J]. Pharmacogenetics, 2001,11(3):217-221.
3. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects[J]. Pharm Res, 2001,18(10):1400-1404.
4. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene[J]. Clin Pharmacol Ther, 2002,72(5):584-594.
5. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms[J]. Eur J Clin Pharmacol, 2003,58(12):809-812.
6. Verstuyft C, Strabach S, El-Morabet H, et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition[J]. Clin Pharmacol Ther, 2003,73(1):51-60.
7. + natural killer cells[J]. Pharmacogenetics, 2001, 11(4):293-298.
8. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study[J]. Lancet, 2002,359(9300):30-36.
9. Brumme Z L, Dong W W, Chan KJ, et al. Influence of polymorphisms within the CX3 CR1 and MDR-1 genes on initial antiretroviral therapy response[J]. AIDS, 2003,17(2):201-208.
10. Haas D W, Smeaton L M, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS clinical trials group study[J]. J Infect Dis, 2005,192(1):1931-1942.
11. Almond L M, Edirisinghe D, Dalton M, et al. Intracellular and plasma pharmacokinetics of nevirapine in HIV-infected individuals[J]. Clin Pharmacol Ther, 2005,78(2):132-142.
12. Kim R B, Leake B F, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans[J]. Clin Pharmacol Ther, 2001,70(2):189-199.
13. Tirana R G, Leake B F, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans[J]. J Biol Chem, 2001,276(38):35669-35675.
14. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis[J]. J Pharmacol Exp Ther, 2002,302(2):804-813.
15. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)[J]. Pharmacogenetics, 2004,14(7):429-440.
16. Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics[J]. Clin Pharmacol Ther, 2003,73(6):554-565.
17. Ho R H, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants[J]. Pharmacogenet Genomics, 2007,17(8):647-656.
18. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics[J]. Clin Pharmacol Ther, 2004,75(5):415-421.
19. Zhang W, Chen B L, Ozdemir V, et al. SLCO1B1 521T→ C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients[J]. Br J Clin Pharmacol, 2007,64(3):346-352.
20. Ho R H, Wang Y, Leake BF, et al. Multiple OATP transporters mediate the cellular uptake of rosuvastatin[J]. Clin Pharmacol Ther, 2005,77(3):11-51.
21. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pravastatin in healthy volunteers[J]. Clin Pharmacol Ther, 2007,82(5):541-547.
22. Pasanen M K, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid[J]. Pharmacogenet Genomics, 2006,16(12):873-879.
23. Morimoto K, Oishi T, Ueda S, et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy[J]. Drug Metab Pharmacokinet, 2004,19(6):453-455.
24. Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the ostrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8)[J]. Pharmacogenetics, 2004,14(7):441-452.
25. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry[J]. J Biol Chem, 2005,280(10):9610-9617.